[51] reported a higher detection rate using the Parsortix than the CellSearch® system in patients with NSCLC receiving different therapy regimens, attributing the difference to the heterogeneity and low EpCAM expression of some CTCs and therefore to the inability of EpCAM‐based CellSearch® to detect certain subpopulations. This evidence concerns the gene EPCAM and non-small cell lung carcinoma.